  
 |
A Strategic Assessment of Oncology Innovations
The objective of this report, issued September 1998, is to identify, critique, and rate emerging cancer technologies available for in-licensing. The analyses are fresh and discriminating - both the merits and the pitfalls of each technology have been stringently reviewed against a number of relevant criteria embracing both product (e.g., mode of action) and company source (e.g., management, pipeline). In the final analysis, readers will be uniquely positioned to act quickly on expanding or launching their cancer product line.
Table of Contents
Action Report
I. Executive Summary
II. Introduction
III. Report Methodology
IV. Market/Technology Dynamics
V. Breast Cancer
VI. Colorectal Cancer
VII. Hepatobiliary Cancer
VIII. Non-Hodgkins Lymphoma
IX. Non-Small Cell Lung Cancer
X. Ovarian Cancer
XI. Pancreatic Cancer
XII. Prostate Cancer
XIII.-XXII. Novel Oncology Products/Technologies Under Clinical Development
XXIII. Reimbursement
XXIV. Conclusions
XXV. Appendices
Oncology Panelists
Roland Greenberg, Ph.D.
President
Troy Technology Consulting, Inc.
Darlene W. Hayes
Attorney at Law
Gray Cary Ware & Freidenrich LLP
Ian Hicks
Founder
Hicks Associates
Steven M. Larson, M.D.
Chief, Nuclear Medicine Service
Department of Radiology
Memorial Sloan-Kettering Cancer Center
Isadore Pike, M.D.
Vice President, Clinical & Medical Operations
Quintiles Oncology Therapeutics
Alan Saven, M.D.
Head of Cancer Division
Scripps Cancer Center
Oncology Editorial Board
Malin Dollinger, M.D., F.A.C.P.
Medical Oncology
John Wayne Cancer Institute
John C. Reed, M.D., Ph.D.
Scientific Director
The Burnham Institute
Branimir I. Sikic, M.D.
Director, General Clinical Research Center
Professor of Medicine
Stanford University School of Medicine
H. William Strauss, M.D.
Chairman of Nuclear Medicine
Stanford University School of Medicine
|
|
